Genentech Launches $1B+ RNA Collaboration with Ribometrix
Ribometrix has shown that several RNAs associated with disease contain structural pockets—clefts and crevices (highlighted)—that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based company. [Ribometrix]
January 6, 2021
Ribometrix has shown that several RNAs associated with disease contain structural pockets—clefts and crevices (highlighted)—that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based company. [Ribometrix]